Literature DB >> 2173726

Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells.

H Itoh1, R E Pratt, V J Dzau.   

Abstract

Vascular remodeling is central to the pathophysiology of hypertension and atherosclerosis. Recent evidence suggests that vasoconstrictive substances, such as angiotensin II (AII), may function as a vascular smooth muscle growth promoting substance. To explore the role of the counterregulatory hormone, atrial natriuretic polypeptide (ANP) in this process, we examined the effect of ANP (alpha-rat ANP [1-28]) on the growth characteristics of cultured rat aortic smooth muscle (RASM) cells. ANP (10(-7) M) significantly suppressed the proliferative effect of 1% and 5% serum as measured by 3H-thymidine incorporation and cell number, confirming ANP as an antimitogenic factor. In quiescent RASM cells, ANP (10(-7), 10(-6) M) significantly suppressed the basal incorporations of 3H-uridine and leucine by 50 and 30%, respectively. ANP (10(-7), 10(-6) M) also suppressed AII-induced RNA and protein syntheses (by 30-40%) with the concomitant reduction of the cell size. Furthermore, ANP also significantly attenuated the increase of 3H-uridine and leucine incorporations caused by transforming growth factor-beta (4 x 10(-11), 4 x 10(-10) M), a potent hypertrophic factor. These results indicate that ANP possesses an antihypertrophic action on vascular smooth muscle cells. Down-regulation of protein kinase C by 24-h treatment with phorbol 12,13-dibutyrate did not inhibit ANP-induced suppression on 3H-uridine incorporation. Based on the observation that ANP was more potent than a ring-deleted analogue of ANP on inhibiting 3H-uridine incorporation, we conclude that the ANP's inhibitory effect is primarily mediated via the activation of a guanylate cyclase-linked ANP receptor(s). Indeed 8-bromo cGMP mimicked the antihypertrophic action of ANP. Accordingly, we speculate that in addition to its vasorelaxant and natriuretic effects, the antihypertrophic action of ANP observed in the present study may serve as an additional compensatory mechanism of ANP in hypertension.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2173726      PMCID: PMC296921          DOI: 10.1172/JCI114893

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  Physiological role of silent receptors of atrial natriuretic factor.

Authors:  T Maack; M Suzuki; F A Almeida; D Nussenzveig; R M Scarborough; G A McEnroe; J A Lewicki
Journal:  Science       Date:  1987-10-30       Impact factor: 47.728

2.  Angiotensin II induces c-fos mRNA in aortic smooth muscle. Role of Ca2+ mobilization and protein kinase C activation.

Authors:  M B Taubman; B C Berk; S Izumo; T Tsuda; R W Alexander; B Nadal-Ginard
Journal:  J Biol Chem       Date:  1989-01-05       Impact factor: 5.157

3.  Atrial natriuretic factor (ANF) inhibits the growth and the secretory activity of rat adrenal zona glomerulosa in vivo.

Authors:  G Mazzocchi; P Rebuffat; G G Nussdorfer
Journal:  J Steroid Biochem       Date:  1987-12       Impact factor: 4.292

4.  Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones.

Authors:  F Fuller; J G Porter; A E Arfsten; J Miller; J W Schilling; R M Scarborough; J A Lewicki; D B Schenk
Journal:  J Biol Chem       Date:  1988-07-05       Impact factor: 5.157

5.  A novel biological effect of atrial natriuretic hormone: inhibition of mesangial cell mitogenesis.

Authors:  A Johnson; F Lermioglu; U C Garg; R Morgan-Boyd; A Hassid
Journal:  Biochem Biophys Res Commun       Date:  1988-04-29       Impact factor: 3.575

Review 6.  Cell biology of vascular hypertrophy in systemic hypertension.

Authors:  V J Dzau; G H Gibbons
Journal:  Am J Cardiol       Date:  1988-10-05       Impact factor: 2.778

7.  Gamma-atrial natriuretic polypeptide (gamma ANP)-derived peptides in human plasma: cosecretion of N-terminal gamma ANP fragment and alpha ANP.

Authors:  H Itoh; K Nakao; A Sugawara; Y Saito; M Mukoyama; N Morii; T Yamada; S Shiono; H Arai; K Hosoda
Journal:  J Clin Endocrinol Metab       Date:  1988-09       Impact factor: 5.958

8.  Growth inhibitory activity of atrial natriuretic factor in rat glomerular mesangial cells.

Authors:  R G Appel
Journal:  FEBS Lett       Date:  1988-09-26       Impact factor: 4.124

9.  Effects of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension.

Authors:  B I Levy; J B Michel; J L Salzmann; M Azizi; P Poitevin; M Safar; J P Camilleri
Journal:  Circ Res       Date:  1988-07       Impact factor: 17.367

10.  Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells.

Authors:  G K Owens; A A Geisterfer; Y W Yang; A Komoriya
Journal:  J Cell Biol       Date:  1988-08       Impact factor: 10.539

View more
  44 in total

1.  Dynamics of Vascular Remodeling: An Overview and Bibliography.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 2.  Natriuretic peptide receptor: structure and signaling.

Authors:  Kunio S Misono
Journal:  Mol Cell Biochem       Date:  2002-01       Impact factor: 3.396

3.  Cardiac fibroblasts produce leukemia inhibitory factor and endothelin, which combine to induce cardiac myocyte hypertrophy in vitro.

Authors:  K L King; J Lai; J Winer; E Luis; R Yen; J Hooley; P M Williams; J P Mather
Journal:  Endocrine       Date:  1996-08       Impact factor: 3.633

Review 4.  Role of nitric oxide in progression and regression of atherosclerosis.

Authors:  J P Cooke
Journal:  West J Med       Date:  1996-05

5.  Endogenous vascular synthesis of B-type and C-type natriuretic peptides in the rainbow trout.

Authors:  Keven R Johnson; Todd M Hoagland; Kenneth R Olson
Journal:  J Exp Biol       Date:  2011-08-15       Impact factor: 3.312

6.  Differential effects of natriuretic peptides on arterial and venous coronary artery bypass conduits.

Authors:  Hao G Nguyen; Amit Korach; Chey Collura; Benjamin R Eskenazi; Joseph A Vita; Oz M Shapira
Journal:  Ann Thorac Surg       Date:  2009-03       Impact factor: 4.330

7.  Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II.

Authors:  H Itoh; M Mukoyama; R E Pratt; G H Gibbons; V J Dzau
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

8.  Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.

Authors:  R Morishita; G H Gibbons; K E Ellison; M Nakajima; L Zhang; Y Kaneda; T Ogihara; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

9.  Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B.

Authors:  Thomas H Langenickel; Jens Buttgereit; Ines Pagel-Langenickel; Maren Lindner; Jan Monti; Knut Beuerlein; Nidal Al-Saadi; Ralph Plehm; Elena Popova; Jens Tank; Rainer Dietz; Roland Willenbrock; Michael Bader
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-14       Impact factor: 11.205

10.  Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system".

Authors:  S Suga; K Nakao; H Itoh; Y Komatsu; Y Ogawa; N Hama; H Imura
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.